Annovis Bio slips after pricing $15M equity offering
Annovis Bio's stock experienced a decline after the company announced the pricing of a $15 million underwritten public offering of its common stock. T...
Annovis Bio's stock experienced a decline after the company announced the pricing of a $15 million underwritten public offering of its common stock. T...
Neutral
Annovis Bio (ANVS) is seeking stockholder approval at its virtual 2026 Annual Meeting on June 17, 2026, to expand its 2019 Equity Incentive Plan. The ...